Childhood ependymoma

Summary

Childhood ependymoma (MONDO:0003478) is a disease with 1 cohort gene and 121 clinical trials. Molecularly, SEC61G::EGFR Fusion confers sensitivity to Gefitinib in Childhood Ependymoma (CIViC Level A); 1 further subtype–drug associations are mapped below. Top therapeutic interventions include carboplatin, larotrectinib, and lapatinib.

At a glance

• Cohort genes: 1
• Clinical trials: 121
• Precision-medicine evidence (CIViC): 2 subtype–drug associations

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	childhood ependymoma
Mondo ID	MONDO:0003478
MeSH	C531673
DOID	DOID:5509
NCIT	C8578
UMLS	C1851584
MedGen	343609
GARD	0023523
Is cancer (heuristic)	no

Also known as: childhood ependymoma · ependymoma · ependymoma of childhood · paediatric ependymoma · pediatric ependymoma

Data availability: 12 cell lines · 1 intOGen driver record.

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › nervous system neoplasm › neuroepithelial neoplasm › glioma › ependymal tumor › ependymoma › childhood ependymoma

Related subtypes (7): cellular ependymoma, spinal cord ependymoma, tanycytic ependymoma, papillary ependymoma, clear cell ependymoma, brain stem ependymoma, low grade ependymoma

Subtypes (1): pediatric supratentorial ependymoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 4 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
ERBB2	Orphanet:213726	Serous carcinoma of the corpus uteri
ERBB2	Orphanet:2800	Extramammary Paget disease
ERBB2	Orphanet:388	Hirschsprung disease
ERBB2	Orphanet:99976	Adenocarcinoma of the oesophagus and oesophagogastric junction

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
civic_only	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
ERBB2	HGNC:3430	ENSG00000141736	P04626	Receptor tyrosine-protein kinase erbB-2	civic_evidence

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
ERBB2	Receptor tyrosine-protein kinase erbB-2	Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding.

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	1	27.7×	0.036

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
ERBB2	Kinase	yes	2.7.10.1	Rcpt_L-dom, Prot_kinase_dom, Ser-Thr/Tyr_kinase_cat_dom

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
lower esophagus mucosa	1
right uterine tube	1
sural nerve	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
ERBB2	276	ubiquitous	marker	lower esophagus mucosa, right uterine tube, sural nerve

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
ERBB2	9,659

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
ERBB2	P04626	63

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 33. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
PLCG1 events in ERBB2 signaling	1	2855.0×	0.001	ERBB2
Drug-mediated inhibition of ERBB2 signaling	1	2855.0×	0.001	ERBB2
Resistance of ERBB2 KD mutants to trastuzumab	1	2855.0×	0.001	ERBB2
Resistance of ERBB2 KD mutants to sapitinib	1	2855.0×	0.001	ERBB2
Resistance of ERBB2 KD mutants to tesevatinib	1	2855.0×	0.001	ERBB2
Resistance of ERBB2 KD mutants to neratinib	1	2855.0×	0.001	ERBB2
Resistance of ERBB2 KD mutants to osimertinib	1	2855.0×	0.001	ERBB2
Resistance of ERBB2 KD mutants to afatinib	1	2855.0×	0.001	ERBB2
Resistance of ERBB2 KD mutants to AEE788	1	2855.0×	0.001	ERBB2
Resistance of ERBB2 KD mutants to lapatinib	1	2855.0×	0.001	ERBB2
Drug resistance in ERBB2 TMD/JMD mutants	1	2855.0×	0.001	ERBB2
GRB7 events in ERBB2 signaling	1	1903.3×	0.001	ERBB2
Constitutive Signaling by Overexpressed ERBB2	1	951.7×	0.002	ERBB2
Downregulation of ERBB2:ERBB3 signaling	1	815.7×	0.002	ERBB2
ERBB2 Activates PTK6 Signaling	1	815.7×	0.002	ERBB2
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors	1	761.3×	0.002	ERBB2
Developmental Lineage of Mammary Stem Cells	1	761.3×	0.002	ERBB2
ERBB2 Regulates Cell Motility	1	713.8×	0.002	ERBB2
PI3K events in ERBB2 signaling	1	671.8×	0.002	ERBB2
Signaling by ERBB2 ECD mutants	1	671.8×	0.002	ERBB2
GRB2 events in ERBB2 signaling	1	634.4×	0.002	ERBB2
Sema4D induced cell migration and growth-cone collapse	1	571.0×	0.003	ERBB2
Developmental Lineage of Mammary Gland Myoepithelial Cells	1	543.8×	0.003	ERBB2
SHC1 events in ERBB2 signaling	1	475.8×	0.003	ERBB2
Signaling by ERBB2 TMD/JMD mutants	1	475.8×	0.003	ERBB2
Developmental Lineage of Mammary Gland Luminal Epithelial Cells	1	456.8×	0.003	ERBB2
Signaling by ERBB2 KD Mutants	1	423.0×	0.003	ERBB2
Downregulation of ERBB2 signaling	1	380.7×	0.003	ERBB2
Signaling by ERBB2	1	346.1×	0.003	ERBB2
Constitutive Signaling by Aberrant PI3K in Cancer	1	126.9×	0.009	ERBB2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
immature T cell proliferation in thymus	1	3370.4×	0.004	ERBB2
negative regulation of immature T cell proliferation in thymus	1	2808.7×	0.004	ERBB2
ERBB2-ERBB4 signaling pathway	1	2808.7×	0.004	ERBB2
regulation of microtubule-based process	1	1872.4×	0.004	ERBB2
ERBB2-ERBB3 signaling pathway	1	1685.2×	0.004	ERBB2
ERBB2-EGFR signaling pathway	1	1685.2×	0.004	ERBB2
enzyme-linked receptor protein signaling pathway	1	1296.3×	0.004	ERBB2
Schwann cell development	1	1053.2×	0.005	ERBB2
neurotransmitter receptor localization to postsynaptic specialization membrane	1	802.5×	0.005	ERBB2
motor neuron axon guidance	1	702.2×	0.005	ERBB2
positive regulation of MAP kinase activity	1	648.1×	0.005	ERBB2
positive regulation of transcription by RNA polymerase I	1	648.1×	0.005	ERBB2
positive regulation of Rho protein signal transduction	1	581.1×	0.005	ERBB2
regulation of ERK1 and ERK2 cascade	1	581.1×	0.005	ERBB2
positive regulation of protein targeting to membrane	1	561.7×	0.005	ERBB2
neuromuscular junction development	1	526.6×	0.005	ERBB2
peptidyl-tyrosine phosphorylation	1	421.3×	0.005	ERBB2
regulation of angiogenesis	1	421.3×	0.005	ERBB2
oligodendrocyte differentiation	1	421.3×	0.005	ERBB2
semaphorin-plexin signaling pathway	1	401.2×	0.005	ERBB2
cellular response to growth factor stimulus	1	318.0×	0.006	ERBB2
cellular response to epidermal growth factor stimulus	1	318.0×	0.006	ERBB2
positive regulation of cell adhesion	1	271.8×	0.006	ERBB2
myelination	1	251.5×	0.006	ERBB2
epidermal growth factor receptor signaling pathway	1	247.8×	0.006	ERBB2
positive regulation of epithelial cell proliferation	1	244.2×	0.006	ERBB2
wound healing	1	227.7×	0.006	ERBB2
positive regulation of translation	1	227.7×	0.006	ERBB2
phosphatidylinositol 3-kinase/protein kinase B signal transduction	1	210.7×	0.007	ERBB2
positive regulation of cell growth	1	183.2×	0.007	ERBB2

Therapeutics

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 0

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
ERBB2	CLOTRIMAZOLE

Top cohort targets by molecule count

Symbol	Molecules	Max phase
ERBB2	83	4

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
CLOTRIMAZOLE	4	ERBB2
ERLOTINIB HYDROCHLORIDE	4	ERBB2
PONATINIB	4	ERBB2
AFATINIB	4	ERBB2
LAPATINIB DITOSYLATE	4	ERBB2
SORAFENIB	4	ERBB2
NERATINIB	4	ERBB2
IBRUTINIB	4	ERBB2
AFATINIB DIMALEATE	4	ERBB2
CABOZANTINIB	4	ERBB2
DACOMITINIB	4	ERBB2
DACOMITINIB ANHYDROUS	4	ERBB2
VANDETANIB	4	ERBB2
TRIBROMSALAN	4	ERBB2
BOSUTINIB	4	ERBB2
BITHIONOL	4	ERBB2
ASTEMIZOLE	4	ERBB2
EBASTINE	4	ERBB2
OSIMERTINIB	4	ERBB2
BRIGATINIB	4	ERBB2
ACALABRUTINIB	4	ERBB2
ZANUBRUTINIB	4	ERBB2
TUCATINIB	4	ERBB2
TIRABRUTINIB	4	ERBB2
PACLITAXEL	4	ERBB2
LAZERTINIB	4	ERBB2
HEXACHLOROPHENE	4	ERBB2
DOXORUBICIN	4	ERBB2
DASATINIB	4	ERBB2
ERLOTINIB	4	ERBB2

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
ERBB2	1,221	Binding:1136, Functional:79, ADMET:6

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
ERBB2	2.7.10.1	receptor protein-tyrosine kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
ERBB2	1,221

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

28 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
CLOTRIMAZOLE	4	ERBB2
ERLOTINIB HYDROCHLORIDE	4	ERBB2
PONATINIB	4	ERBB2
AFATINIB	4	ERBB2
LAPATINIB DITOSYLATE	4	ERBB2
SORAFENIB	4	ERBB2
IBRUTINIB	4	ERBB2
AFATINIB DIMALEATE	4	ERBB2
CABOZANTINIB	4	ERBB2
DACOMITINIB	4	ERBB2
DACOMITINIB ANHYDROUS	4	ERBB2
VANDETANIB	4	ERBB2
TRIBROMSALAN	4	ERBB2
BOSUTINIB	4	ERBB2
BITHIONOL	4	ERBB2
ASTEMIZOLE	4	ERBB2
EBASTINE	4	ERBB2
OSIMERTINIB	4	ERBB2
ACALABRUTINIB	4	ERBB2
ZANUBRUTINIB	4	ERBB2
TUCATINIB	4	ERBB2
TIRABRUTINIB	4	ERBB2
PACLITAXEL	4	ERBB2
LAZERTINIB	4	ERBB2
HEXACHLOROPHENE	4	ERBB2
DOXORUBICIN	4	ERBB2
DASATINIB	4	ERBB2
ERLOTINIB	4	ERBB2

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	ERBB2
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 121.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	48
PHASE2	39
Not specified	21
PHASE1/PHASE2	6
EARLY_PHASE1	3
PHASE3	2
PHASE2/PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02265770	PHASE2/PHASE3	RECRUITING	An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma
NCT00517959	PHASE3	UNKNOWN	SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors
NCT00749723	PHASE2/PHASE3	COMPLETED	Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children
NCT01096368	PHASE3	COMPLETED	Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma
NCT00840047	PHASE2	ACTIVE_NOT_RECRUITING	Methionine PET/CT Studies In Patients With Cancer
NCT01356290	PHASE2	RECRUITING	Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
NCT02125786	PHASE2	ACTIVE_NOT_RECRUITING	A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma
NCT03155620	PHASE2	ACTIVE_NOT_RECRUITING	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
NCT03210714	PHASE2	ACTIVE_NOT_RECRUITING	Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
NCT03213652	PHASE2	ACTIVE_NOT_RECRUITING	Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
NCT03213704	PHASE2	ACTIVE_NOT_RECRUITING	Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
NCT03698994	PHASE2	ACTIVE_NOT_RECRUITING	Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
NCT04049669	PHASE2	ACTIVE_NOT_RECRUITING	Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
NCT04195555	PHASE2	ACTIVE_NOT_RECRUITING	Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
NCT04284774	PHASE2	ACTIVE_NOT_RECRUITING	Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04320888	PHASE2	ACTIVE_NOT_RECRUITING	Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04374305	PHASE2	RECRUITING	Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
NCT04743661	PHASE2	ACTIVE_NOT_RECRUITING	131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
NCT06161519	PHASE1/PHASE2	RECRUITING	PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
NCT06485908	PHASE1/PHASE2	NOT_YET_RECRUITING	Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and Ependymoma
NCT06521567	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
NCT06639607	PHASE1/PHASE2	NOT_YET_RECRUITING	PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma
NCT06804655	PHASE2	NOT_YET_RECRUITING	Pharmacoscopy for Patients With Refractory Primary Brain Tumors
NCT07424092	PHASE2	RECRUITING	Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors
NCT00003479	PHASE2	TERMINATED	Antineoplaston Therapy in Treating Patients With Ependymoma
NCT00004078	PHASE2	COMPLETED	Irinotecan in Treating Children With Refractory Solid Tumors
NCT00091182	PHASE2	COMPLETED	Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
NCT00095940	PHASE1/PHASE2	COMPLETED	Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
NCT00381797	PHASE2	COMPLETED	Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
NCT00520936	PHASE2	COMPLETED	A Study of Pemetrexed in Children With Recurrent Cancer
NCT01088035	PHASE2	TERMINATED	Carboplatin as a Radiosensitizer in Treating Childhood Ependymoma
NCT01247922	PHASE2	TERMINATED	Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205
NCT01288235	PHASE2	COMPLETED	Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation
NCT01295944	PHASE2	COMPLETED	Carboplatin and Bevacizumab for Recurrent Ependymoma
NCT01462695	PHASE2	COMPLETED	Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
NCT01836549	PHASE2	TERMINATED	Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
NCT02155920	PHASE2	COMPLETED	Everolimus for Children With Recurrent or Progressive Ependymoma
NCT02684071	PHASE2	TERMINATED	Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors
NCT02689336	PHASE2	WITHDRAWN	Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
NCT03095248	PHASE2	TERMINATED	Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CARBOPLATIN	4	4
LAROTRECTINIB	4	4
LAPATINIB	4	3
SELUMETINIB	4	3
2-MERCAPTOETHANESULFONIC ACID	4	2
ENSARTINIB	4	2
ERDAFITINIB	4	2
IVOSIDENIB	4	2
SELPERCATINIB	4	2
TAZEMETOSTAT	4	2
VALPROIC ACID	4	2
VEMURAFENIB	4	2
BRIGATINIB	4	1
DOSTARLIMAB	4	1
ETOPOSIDE PHOSPHATE	4	1
FENOFIBRIC ACID	4	1
FLUDEOXYGLUCOSE F 18	4	1
IMETELSTAT SODIUM	4	1
LIOTHYRONINE	4	1
LOMUSTINE	4	1
NERATINIB	4	1
RETIFANLIMAB	4	1
ROMIDEPSIN	4	1
SUNITINIB MALATE	4	1
TEMOZOLOMIDE	4	1
TERFENADINE	4	1
THIOTEPA	4	1
VALACYCLOVIR	4	1
VINCRISTINE	4	1
TIPIFARNIB	3	2

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 2 predictive associations from 2 curated evidence items.

Molecular subtype	Therapy	Effect	Level	CIViC
SEC61G::EGFR Fusion	Gefitinib	Sensitivity/Response	CIViC A	EID10933
ERBB2 Amplification	Lapatinib	Sensitivity/Response	CIViC B	EID9778